Financial results - BIOGEN VET SRL

Financial Summary - Biogen Vet Srl
Unique identification code: 37677709
Registration number: J04/897/2017
Nace: 8621
Sales - Ron
470.784
Net Profit - Ron
-289.433
Employee
18
The most important financial indicators for the company Biogen Vet Srl - Unique Identification Number 37677709: sales in 2023 was 470.784 euro, registering a net profit of -289.433 euro and having an average number of 18 employees. Firma isi desfasoara activitatea in domeniul Activitati de asistenta medicala generala having the NACE code 8621.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Biogen Vet Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR - - - 16.828 152.117 260.857 1.616.772 1.371.208 596.238 470.784
Total Income - EUR - - - 20.434 160.693 266.991 1.621.679 1.376.189 601.335 524.555
Total Expenses - EUR - - - 9.204 67.692 79.383 987.956 738.518 595.729 813.988
Gross Profit/Loss - EUR - - - 11.230 93.001 187.608 633.723 637.671 5.606 -289.433
Net Profit/Loss - EUR - - - 11.061 91.475 184.999 584.122 628.958 5.606 -289.433
Employees - - - 3 5 6 0 10 23 18
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales decreased by -20.8%, from 596.238 euro in the year 2022, to 470.784 euro in 2023. The Net Profit decreased by -5.589 euro, from 5.606 euro in 2022, to 0 in the last year.

Check the financial reports for the company - Biogen Vet Srl

Rating financiar

Financial Rating -
Biogen Vet Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Biogen Vet Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Biogen Vet Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Biogen Vet Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Biogen Vet Srl - CUI 37677709

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets - - - 43.465 37.573 31.850 182.217 1.458.160 1.741.171 1.830.417
Current Assets - - - 58.618 129.222 224.465 1.073.054 570.845 767.828 818.500
Inventories - - - 0 2 117 8.611 9.665 189.181 196.765
Receivables - - - 52.547 78.660 201.629 558.728 450.921 554.303 617.690
Cash - - - 6.071 50.561 22.720 505.714 110.259 24.345 4.045
Shareholders Funds - - - 11.105 102.376 195.689 776.102 1.177.493 1.186.752 893.720
Social Capital - - - 44 43 42 41 40 41 40
Debts - - - 49.404 28.703 31.662 434.466 852.630 1.327.764 1.758.215
Income in Advance - - - 41.574 35.716 30.029 46.162 19.221 14.474 9.637
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "8621 - 8621"
CAEN Financial Year 8621
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 818.500 euro in 2023 which includes Inventories of 196.765 euro, Receivables of 617.690 euro and cash availability of 4.045 euro.
The company's Equity was valued at 893.720 euro, while total Liabilities amounted to 1.758.215 euro. Equity decreased by -289.433 euro, from 1.186.752 euro in 2022, to 893.720 in 2023. The Debt Ratio was 66.1% in the year 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Biogen Vet Srl

Comments - Biogen Vet Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.